D. E. Shaw & Co., Inc. Edgewise Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 473,680 shares of EWTX stock, worth $8.66 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
473,680
Previous 31,950
1382.57%
Holding current value
$8.66 Million
Previous $349,000
2375.36%
% of portfolio
0.01%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding EWTX
# of Institutions
129Shares Held
76.3MCall Options Held
14.7KPut Options Held
14.8K-
Orbimed Advisors LLC San Diego, CA15MShares$275 Million6.17% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$107 Million1.35% of portfolio
-
Black Rock Inc. New York, NY5.17MShares$94.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.02MShares$73.4 Million0.0% of portfolio
-
Viking Global Investors LP3.34MShares$61 Million0.23% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.15B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...